Cutting-edge innovation will help fuel better cancer care, today and tomorrow. The Research and Development team at Foundation Medicine is relentless in that pursuit of a richer science. Leveraging scientific insights through software, we help transform cancer care with one significant advantage: access to one of the largest genomic databases in the world.
Rediscover your curiosity and passion for life-changing science with us.
Dr. Hegde joined Foundation Medicine as the Chief Scientific Officer in August 2019. Her team comprises of Cancer Genomics, Research and Early Development, Computational Biology, Translational Strategy, Franchise Development, and Product Development (inclusive of Assay Development, Companion Diagnostic Development Operations, Regulatory, and Biomarkers and Biometrics.)
Dr. Hegde has spent nearly two decades in the biopharmaceutical industry, developing integrated research strategies in precision medicine, with a proven track record in research, drug development, registration, and commercialization of therapeutics.
Current Open Roles on the Team:
|Co-Op, Regulatory Affairs (Graduate)||Regulatory||100438||Cambridge||Massachusetts||United States||Cambridge, Massachusetts, United States||Regulatory||About the Job The Co-op, Regulatory Affairs supports the regulatory submissions process through development of regulatory strategy and submission of materials to Health Authorities and Regulatory Bodies (e.g., FDA) for approval of novel platforms...|
|Co-op, Cancer Genomics Research (Undergraduate)||Cancer Genomics||100400||Cambridge||Massachusetts||United States||Cambridge, Massachusetts, United States||Cancer Genomics||About the Job The Co-op, Cancer Genomics Research works with the Cancer Genomics team in Product Development. This position is involved with the investigation, implementation, and validation of computational methods for the development of clinica...|
|Principal Scientist Computational Biology||Computational Biology||100394||Boston||Massachusetts||United States||Boston, Massachusetts, United States||Computational Biology||Key Responsibilities • Integrate clinical DNA-seq and RNA-seq diagnostic assays into a unified platform that supports FMI’s product portfolio expansion, in close collaboration with a multidisciplinary team of scientists, engineers and computation...|
|Scientist I Computational Biologist||Computational Biology||100397||Boston||Massachusetts||United States||Boston, Massachusetts, United States||Computational Biology||Key Responsibilities • Work within an interdisciplinary team of molecular biologists, computational biologists, and software engineers focused on developing diagnostic products using massively parallel sequencing of tumor genomic DNA and RNA. • ...|
|Senior Software Engineer||Computational Biology||100379||Boston||Massachusetts||United States||Boston, Massachusetts, United States||Computational Biology||Key Responsibilities • Lead assigned team-wide initiatives, such as: · Investigating design approaches; · Prototyping new technologies; and, · Evaluating technical feasibility. • Develop FMI’s software; in particular, the CompBio Genomi...|
|Software Engineer II||Computational Biology||100378||Boston||Massachusetts||United States||Boston, Massachusetts, United States||Computational Biology||Computational Biology is a diverse team of software engineers and computational biologists creating products focused on genetic alterations and biomarkers in DNA and RNA. The Software Engineer II, Computational Biology will help build and maintain...|
|Senior Scientist I, Early Research & Development||Research and Early Development||100377||San Diego||California||United States||San Diego, California, United States||Research and Early Development||About the Job The Senior Scientist , Molecular Biology & Sequencing is part of the Research and Early Development team in FMI’s Product Development group. This position explores new technologies and biomarker candidates to address unmet needs...|
|Sr Manager, Franchise Development||Franchise Development||100372||Cambridge||Massachusetts||United States||Cambridge, Massachusetts, United States||Franchise Development||ABOUT THE JOB: The Senior Manager, Franchise Development helps the Franchise Development Lead to lead the design and implementation of a designated product or portion of the clinical product portfolio. The position is responsible for directing re...|
|Lead Automation Engineer||Assay Development||100373||San Diego||California||United States||San Diego, California, United States||Assay Development||About the Job The Lead Automation Engineer is responsible for automating and scaling complex workflows and implementing processes for deployment in clinical laboratories at multiple sites. Involved in all aspects of assay automation development a...|
|Mgr, Regulatory Affairs||Regulatory||100330||Cambridge||Massachusetts||United States||Cambridge, Massachusetts, United States||Regulatory||About the Job The Manager, Regulatory Affairs is responsible for supporting the regulatory function and its activities, the development of regulatory strategy, and contributing the regulatory approval process (including US FDA and other regulator...|
|Senior Scientist Companion Diagnostics||Development Operations||100229||Cambridge||Massachusetts||United States||Cambridge, Massachusetts, United States||Development Operations||Key Responsibilities • Lead, author, and execute development, verification, and validation studies for novel diagnostic next generation sequencing assays. • Lead training on new processes as they pertain to applicable cross-functional participan...|
|Sr Dir, Early Research & Development||Research and Early Development||100108||San Diego||California||United States||San Diego, California, United States||Research and Early Development||About the Job The Senior Director leads the Early Research and Development department and leads systematic reviews of new technologies and biomarker candidates as well as assigned projects to addressing unmet needs in the oncology field. The pos...|
FoundationOne CDx was recently approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel.
Learn more on our blog about how this approval demonstrates the power of cancer precision medicine in action and the role that comprehensive genomic profiling plays.
- Garrett Frampton, PhD, Sr. Director, Cancer Genomics
We are thrilled to announce the FDA approval of FoundationOne®Liquid CDx, our comprehensive liquid biopsy test, for all solid tumors. This approval is such an important milestone because we can now offer oncologists multiple FDA-approved, high-quality comprehensive genomic profiling options. From a simple blood draw, FoundationOne Liquid CDx can provide physicians and patients with molecular insights to guide informed treatment decisions whether that be targeted therapies, clinical trials or immunotherapy.
For more about this approval, click here to read the press release.
The Best of the AACR Journals collection highlights the most-cited articles published in 2018 across the AACR journals. Congratulations to our Director of Cancer Genomics Research, Lee A. Albacker for his most-cited article entitled STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.